ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A10BD19 | B | Linagliptin - 5mg, Empagliflozin - 25mg | 11434 | 142722/1 | GLYXAMBI | 30 | Tablet, film coated | Oral | Mersaco | Rottendorf Pharma GmbH | Germany | 4,162,216 L.L | 23.08 | B | Boehringer Ingelheim International GmbH | Germany | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A10BD19 | B | Linagliptin - 5mg, Empagliflozin - 25mg | 9827 | 178818/1 | GLYXAMBI | 30 | Tablet, film coated | Oral | Mersaco | Boehringer Ingelheim Pharma GmbH & Co KG | Germany | 4,162,216 L.L | 23.08 | B | Boehringer Ingelheim Pty Ltd | Australia | 2/5/2024 | 0 | |
A10BD19 | G | Empagliflozin - 25mg, Linagliptin - 5mg | 11813 | 37524/1 | EMPAGLINE | 30 | Tablet, film coated | Oral | Pharmaline S.A.L. | Pharmaline SAL | Lebanon | 2,237,050 L.L | 23.08 | B | 2/5/2024 | 0 |